General
Preferred name
DARIFENACIN
Synonyms
UK88525 ()
UK-88525 ()
Darifenacin HBr ()
DARIFENACIN HYDROBROMIDE ()
Darifenacin (hydrobromide) ()
UK-88525 (hydrobromide) ()
Enablex ()
Uk-88525-04 (hbr) ()
UK-88525-04 (HYDROBROMIDE) ()
Emselex ()
Darifenacine ()
Darifenacina ()
Darifenacin extended release ()
P&D ID
PD009993
CAS
133099-04-4
133099-07-7
Tags
available
drug
Approved by
FDA
EMA
First approval
2004
Drug indication
urgency urinary incontinence
Overactive bladder
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects[1][2][3][4][5][6].
PRICE 29
DESCRIPTION Darifenacin is a muscarinic acetylcholine M3 receptor antagonist. (GtoPdb)
DESCRIPTION Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects[1][2][3][4][5][6].
PRICE 88
DESCRIPTION Darifenacin is an M3 muscarinic receptor blocker used to treat urinary incontinence. (Enamine Bioactive Compounds)
DESCRIPTION Darifenacin hydrobromide (UK-88525) is a selective muscarinic receptor antagonist used to treat urinary incontinence and overactive bladder syndrome. (TargetMol Bioactive Compound Library)
DESCRIPTION Darifenacin (UK-88525) is a muscarinic receptor M3 antagonist with anticonvulsant activity and can be used to study urinary incontinence and overactive bladder. (TargetMol Bioactive Compound Library)
Compound Sets
27
Cayman Chemical Bioactives
14424
ChEMBL Approved Drugs
CHEMBL1200935
CHEMBL1346
ChEMBL Drugs
CHEMBL1200935
CHEMBL1346
Concise Guide to Pharmacology 2017/18
319
321
Concise Guide to Pharmacology 2019/20
319
321
Concise Guide to Pharmacology 2021/22
319
321
Concise Guide to Pharmacology 2023/24
319
321
Drug Repurposing Hub
DrugBank
DB00496
DrugBank Approved Drugs
DB00496
DrugCentral
784
DrugCentral Approved Drugs
784
DrugMAP
DMWXLYZ
DrugMAP Approved Drugs
DMWXLYZ
Enamine Bioactive Compounds
EBC-11257
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101748
Guide to Pharmacology
319
321
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1346
MedChem Express Bioactive Compound Library
HY-A0012
HY-A0033
NCATS Inxight Approved Drugs
APG9819VLM
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
darifenacin-hydrobromide
TargetMol Bioactive Compound Library
T1534
T62320
VGSC-DB
NA0134
External IDs
61
Properties
(calculated by RDKit )
Molecular Weight
426.23
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
3
cLogP
3.96
TPSA
55.56
Fraction CSP3
0.32
Chiral centers
1.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
mAChR
M3 mAChR
CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Akt
p38 MAPK
AChR
Indication
urinary incontinence
MOA
acetylcholine receptor antagonist
Pathway
Neuroscience
GPCR/G protein
MAPK/ERK Pathway
Neuronal Signaling
PI3K/Akt/mTOR
Therapeutic Class
Urinary antispasmodics
VGSC Target
Nav1.5
Source data